Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Medical Genetics

The Crucial Difference: Legius Syndrome vs. NF1

At a Glance

Legius syndrome causes early skin signs that perfectly mimic Neurofibromatosis type 1 (NF1), leading to frequent misdiagnoses. Unlike NF1, Legius syndrome has no known risk for nerve tumors or optic gliomas. Genetic testing of the SPRED1 and NF1 genes is required to accurately distinguish the two conditions.

For decades, doctors used a set of physical rules created in 1988 (the NIH Clinical Diagnostic Criteria) to diagnose Neurofibromatosis type 1 (NF1) [1][2]. These rules worked well until 2007, when researchers discovered Legius syndrome [3].

Because Legius syndrome “mimics” the early skin signs of NF1, a patient can perfectly meet the old clinical criteria for NF1 but actually have Legius syndrome [3][4]. This distinction is the most important piece of information you can have, as it changes the medical future from one of high-risk tumor surveillance to a much milder path [5][3].

Why the Old Clinical Exams Aren’t Enough

In young children, the first signs of both conditions are nearly identical: multiple café-au-lait spots and freckling in the armpits or groin [3][1]. Under the old 1988 NIH rules, a child with six or more spots and skinfold freckling would be automatically diagnosed with NF1 [1].

However, many of the “heavy” complications of NF1—like tumors on the nerves (neurofibromas) or the eyes (optic gliomas)—often don’t appear until later in childhood or even adulthood [6][3]. This means a person could be misdiagnosed with NF1 for years, causing unnecessary anxiety and intensive medical testing, when they actually have the milder Legius syndrome [3][5].

The 2021 Revised Diagnostic Criteria

To address this widespread confusion, the global medical community officially updated the diagnostic criteria for NF1 and Legius syndrome in 2021 [5]. The new, modernized guidelines formally integrate genetic testing as a core part of the diagnostic process, officially acknowledging that skin spots alone are no longer enough to distinguish between the two conditions [5].

The Importance of Genetic Testing

The only way to definitively tell these two conditions apart is through molecular genetic testing [5][7].

  • The Test: Doctors should use a Next Generation Sequencing (NGS) panel [5]. This is a highly accurate blood or saliva test that looks at both the NF1 gene and the SPRED1 gene at the same time [8][7].
  • The Recommendation: If you or your child have been “clinically diagnosed” with NF1 based only on skin spots, it is strongly recommended to discuss a genetic test with your doctor to confirm which gene is actually involved [3][9].

Clues in the Body and Brain

While genetic testing is the “gold standard,” there are specific medical clues that help doctors distinguish Legius syndrome from NF1:

Feature Legius Syndrome (SPRED1) NF1 (Neurofibromatosis)
Brain MRI Usually clear; lacks “bright spots” [10]. FASI (Focal Areas of Signal Intensity) or “bright spots” are seen in about 90% of children [10].
Eye Exam Usually normal; no tumor-like growths [11]. Lisch nodules (on the iris) or Choroidal nodules (behind the eye) are common signs [12][11].
Tumor Risk None identified for neurofibromas or optic gliomas [5][3]. High risk for benign and malignant nerve tumors [5][13].
Skin Signs Spots, freckling, and eventually benign lipomas in adults [5][14]. Spots, freckling, and eventually raised neurofibromas [5][3].

How Management Diverges

Once a SPRED1 mutation is confirmed, the roadmap for care changes fundamentally:

  1. Stop Tumor Surveillance: You can generally stop the high-intensity screenings for optic gliomas (frequent eye exams) and neurofibromas that are mandatory for NF1 [5][3].
  2. Focus on Development: Instead of looking for tumors, you and your doctors can focus on supporting learning, attention, and daily life [5][13].
  3. Prognosis: You can move forward with the knowledge that Legius syndrome is a much more stable and predictable condition [5].

Back to Home.

Common questions in this guide

How is Legius syndrome different from NF1?
While both conditions cause early skin signs like café-au-lait spots and freckling, Legius syndrome does not carry the high risk of nerve tumors or optic gliomas associated with NF1. Legius syndrome is caused by a SPRED1 gene mutation, whereas NF1 is caused by an NF1 gene mutation.
Can a doctor diagnose Legius syndrome just by looking at skin spots?
No. Because the skin signs of Legius syndrome perfectly mimic the early signs of NF1, a clinical skin exam alone is not enough to distinguish them. The updated 2021 diagnostic criteria recommend molecular genetic testing to tell the two conditions apart definitively.
What genetic test is needed to check for Legius syndrome?
Doctors recommend a Next Generation Sequencing (NGS) panel using a blood or saliva sample. This test looks at both the SPRED1 and NF1 genes at the same time to ensure an accurate diagnosis.
Do patients with Legius syndrome need routine tumor screenings?
Once a SPRED1 mutation is confirmed and Legius syndrome is diagnosed, patients generally do not need the intense tumor screenings and frequent eye exams that are mandatory for NF1. Care usually shifts to focusing on learning and development.
What will an MRI or eye exam show if I have Legius syndrome instead of NF1?
In Legius syndrome, a brain MRI usually lacks the 'bright spots' often seen in NF1. Additionally, an eye exam will typically be normal without the Lisch nodules or choroidal nodules that frequently develop in NF1 patients.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can you confirm that the genetic test ordered was a 'Next Generation Sequencing' (NGS) panel that covers both the NF1 and SPRED1 genes?
  2. 2.Since the clinical criteria were updated in 2021, does the medical team formally integrate genetic findings into their diagnosis process?
  3. 3.The MRI did not show 'Focal Areas of Signal Intensity' (FASI). Does this finding support a Legius diagnosis over NF1?
  4. 4.Since there is a confirmed SPRED1 mutation, can we now discontinue the tumor-specific screenings usually required for NF1?
  5. 5.What specific specialists (e.g., neuro-ophthalmologists) should we see to confirm the absence of NF1-specific eye signs?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Challenges in the diagnosis of neurofibromatosis type 1 (NF1) in young children facilitated by means of revised diagnostic criteria including genetic testing for pathogenic NF1 gene variants.

    Kehrer-Sawatzki H, Cooper DN

    Human genetics 2022; (141(2)):177-191 doi:10.1007/s00439-021-02410-z.

    PMID: 34928431
  2. 2

    Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation.

    Legius E, Messiaen L, Wolkenstein P, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2021; (23(8)):1506-1513 doi:10.1038/s41436-021-01170-5.

    PMID: 34012067
  3. 3

    Legius Syndrome and its Relationship with Neurofibromatosis Type 1.

    Denayer E, Legius E

    Acta dermato-venereologica 2020; (100(7)):adv00093 doi:10.2340/00015555-3429.

    PMID: 32147744
  4. 4

    Family with Legius syndrome (neurofibromatosis type 1-like syndrome).

    Sakai N, Maeda T, Kawakami H, et al.

    The Journal of dermatology 2015; (42(7)):703-5 doi:10.1111/1346-8138.12862.

    PMID: 25981987
  5. 5

    Novel causative variants in Legius syndrome: SPRED1 Genotype spectrum expansion.

    Chelleri C, Brolatti N, De Marco P, et al.

    American journal of medical genetics. Part A 2024; (194(12)):e63824 doi:10.1002/ajmg.a.63824.

    PMID: 39031930
  6. 6

    A novel mutation in NF1 gene of patient with Neurofibromatosis type 1: A case report and functional study.

    Zhang T, Jia C, Dong Z, et al.

    Molecular genetics & genomic medicine 2021; (9(5)):e1643 doi:10.1002/mgg3.1643.

    PMID: 33764694
  7. 7

    One NF1 Mutation may Conceal Another.

    Pacot L, Burin des Roziers C, Laurendeau I, et al.

    Genes 2019; (10(9)) doi:10.3390/genes10090633.

    PMID: 31443423
  8. 8

    The first Slovak Legius syndrome patient carrying the SPRED1 gene mutation.

    Sekelska M, Briatkova L, Olcak T, et al.

    General physiology and biophysics 2017; (36(2)):205-210 doi:10.4149/gpb_2016032.

    PMID: 28150585
  9. 9

    Molecular screening strategies for NF1-like syndromes with café-au-lait macules (Review).

    Zhang J, Li M, Yao Z

    Molecular medicine reports 2016; (14(5)):4023-4029 doi:10.3892/mmr.2016.5760.

    PMID: 27666661
  10. 10

    Significance of the Absence of Focal Areas of Signal Intensity on Brain Magnetic Resonance Imaging Examinations in Legius Syndrome.

    Petrak B, Kraus J, Bendova S, et al.

    Pediatric neurology 2025; (169()):142-147 doi:10.1016/j.pediatrneurol.2025.05.008.

    PMID: 40516232
  11. 11

    Choroidal abnormalities in café-au-lait syndromes: a new differential diagnostic tool?

    Cassiman C, Casteels I, Jacob J, et al.

    Clinical genetics 2017; (91(4)):529-535 doi:10.1111/cge.12873.

    PMID: 27716896
  12. 12

    The absence that makes the difference: choroidal abnormalities in Legius syndrome.

    Tucci A, Saletti V, Menni F, et al.

    Journal of human genetics 2017; (62(11)):1001-1004 doi:10.1038/jhg.2017.78.

    PMID: 28747691
  13. 13

    Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism.

    Legius E, Brems H

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2020; (36(10)):2285-2295 doi:10.1007/s00381-020-04771-8.

    PMID: 32601904
  14. 14

    The RASopathies: Biology, genetics and therapeutic options.

    Longo JF, Carroll SL

    Advances in cancer research 2022; (153()):305-341 doi:10.1016/bs.acr.2021.07.007.

    PMID: 35101235

This page explains the differences between Legius syndrome and NF1 for educational purposes. Always consult a geneticist or your healthcare provider to discuss appropriate genetic testing and clinical management.

Get notified when new evidence is published on Legius syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.